INT5959

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.90
First Reported 1982
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 17
Total Number 17
Disease Relevance 0.98
Pain Relevance 12.43

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Cpe) extracellular space (Cpe) extracellular region (Cpe)
Golgi apparatus (Cpe)
Anatomy Link Frequency
ileum 1
N-18 1
plasma 1
osteoblasts 1
spinal cord 1
Cpe (Mus musculus)
Pain Link Frequency Relevance Heat
Enkephalin 95 100.00 Very High Very High Very High
Dynorphin 26 100.00 Very High Very High Very High
Delta opioid receptors 8 99.58 Very High Very High Very High
Spinal cord 13 99.50 Very High Very High Very High
narcan 16 99.08 Very High Very High Very High
alcohol 3 98.88 Very High Very High Very High
analgesia 9 98.42 Very High Very High Very High
antinociception 7 98.06 Very High Very High Very High
Analgesic 11 98.00 Very High Very High Very High
antidepressant 3 97.64 Very High Very High Very High
Disease Link Frequency Relevance Heat
Neuroblastoma 4 99.76 Very High Very High Very High
Rickets 1 81.88 Quite High
Hyperalgesia 4 77.60 Quite High
Pain 1 76.32 Quite High
Nociception 1 75.00 Quite High
Sprains And Strains 1 74.08 Quite High
Osteoporosis 1 68.28 Quite High
Genetic Predisposition To Disease 1 62.68 Quite High
Stress 3 55.84 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Paradoxical analgesia induced by low doses of naloxone is not potentiated by complete inhibition of enkephalin degradation.
Protein_catabolism (degradation) of enkephalin associated with analgesic, narcan, enkephalin and analgesia
1) Confidence 0.90 Published 1994 Journal Neuropharmacology Section Title Doc Link 7910383 Disease Relevance 0.08 Pain Relevance 1.49
These results suggest that a relative lack of enkephalin peptides trans-synaptically, possibly resulting from enhanced enkephalin degradation may contribute to increase alcohol consumption in C57BL/6J mice.
Protein_catabolism (degradation) of enkephalin associated with enkephalin and alcohol
2) Confidence 0.79 Published 1991 Journal Alcohol. Clin. Exp. Res. Section Abstract Doc Link 1656811 Disease Relevance 0.21 Pain Relevance 0.93
This hypothesis was investigated by using the systemically active mixed inhibitor of enkephalin degrading enzymes, RB 101.
Protein_catabolism (degrading) of enkephalin associated with enkephalin
3) Confidence 0.59 Published 1994 Journal Neuropharmacology Section Abstract Doc Link 7910383 Disease Relevance 0.08 Pain Relevance 0.88
The membrane of mouse neuroblastoma N-18 cells degraded dynorphin-(1-13), dynorphin-(1-17), and Leu-enkephalin.
Protein_catabolism (degraded) of Leu-enkephalin in N-18 associated with neuroblastoma, dynorphin and enkephalin
4) Confidence 0.56 Published 1986 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 2877660 Disease Relevance 0.17 Pain Relevance 0.45
Captopril did not affect the degradation of the two dynorphins and Leu-enkephalin, but inhibited the further cleavage of N-terminal fragments generated from dynorphin-(1-13) by the N-ethylmaleimide-sensitive protease.
Protein_catabolism (degradation) of Leu-enkephalin in cleavage associated with dynorphin and enkephalin
5) Confidence 0.56 Published 1986 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 2877660 Disease Relevance 0.16 Pain Relevance 0.48
The increase in met5-enkephalin content was accompanied by an inhibition, greater than 80%, of the dipeptidyl carboxypeptidase that degrades striatal met5-enkephalin.
Protein_catabolism (degrades) of met5-enkephalin associated with enkephalin
6) Confidence 0.46 Published 1982 Journal Neuropharmacology Section Abstract Doc Link 6750433 Disease Relevance 0.07 Pain Relevance 0.53
Comparisons of metabolite formation in the presence versus the absence of inhibitors with high selectivity for various peptidases demonstrated that a bestatin-sensitive aminopeptidase, presumably aminopeptidase M, as well as enkephalinase and angiotensin converting enzyme, participate in the hydrolysis of enkephalin in mouse plasma.
Protein_catabolism (hydrolysis) of enkephalin in plasma associated with enkephalin
7) Confidence 0.43 Published 1992 Journal Life Sci. Section Abstract Doc Link 1346713 Disease Relevance 0 Pain Relevance 0.59
[Study of a new endogenous inhibitor of enkephalin-degrading enzymes; pharmacological function and metabolism of spinorphin].
Protein_catabolism (degrading) of enkephalin associated with enkephalin
8) Confidence 0.42 Published 1993 Journal Masui Section Title Doc Link 8267798 Disease Relevance 0 Pain Relevance 0.63
With the aim of possibly studying the local activity of brain enkephalinergic pathways by autoradiography and positron emission tomography, preliminary competition experiments of [3H]diprenorphine binding in mouse brain were carried out after i.v. administration of the first systemically-active mixed inhibitor of enkephalin degrading enzymes RB 101 (N(R,S)-2-benzyl-3[(S)-(2-amino-4-methylthiobutyldithio]-1-oxoprop yl]- L-phenylalanine benzyl ester).
Protein_catabolism (degrading) of enkephalin in brain associated with positron emission tomography and enkephalin
9) Confidence 0.40 Published 1992 Journal Brain Res. Section Abstract Doc Link 1319268 Disease Relevance 0.06 Pain Relevance 0.54
Spinorphin has a high inhibitory activity against enkephalin degrading enzymes when compared to the various hydrolysis products.
Protein_catabolism (degrading) of enkephalin associated with enkephalin
10) Confidence 0.32 Published 1993 Journal Masui Section Abstract Doc Link 8267798 Disease Relevance 0 Pain Relevance 0.67
Spinorphin, a potent inhibitor of enkephalin degrading enzyme isolated from the bovine spinal cord, produces a dose-related inhibition of electrically evoked contractions of both MVD (mouse vas deferens) and GPI (guinea-pig ileum).
Protein_catabolism (degrading) of enkephalin in ileum associated with enkephalin and spinal cord
11) Confidence 0.32 Published 1993 Journal Masui Section Abstract Doc Link 8267798 Disease Relevance 0 Pain Relevance 0.38
The attenuation of the [D-Ala2]deltorphin II-induced antinociception caused by pretreatment with DOR AS oligo given i.t. daily was blocked by co-pretreatment with naltriben (14.5 nmol), a delta-opioid receptor antagonist, but was markedly enhanced by concomitant pretreatment with thiorphan (19.7 nmol) or bestatin (14.5 nmol), which inhibits the degradation of endogenously released Met-enkephalin.
Protein_catabolism (degradation) of Met-enkephalin associated with antinociception, antagonist, enkephalin and opioid receptor
12) Confidence 0.28 Published 1997 Journal Psychopharmacology (Berl.) Section Abstract Doc Link 9372533 Disease Relevance 0 Pain Relevance 1.06
Systemic administration of RB 101, a complete inhibitor of the enkephalin degrading enzymes, has been reported to induce naltrindole-reversed antidepressant-like effects in the conditioned suppression of motility (CSM) test in mice.
Protein_catabolism (degrading) of enkephalin associated with antidepressant and enkephalin
13) Confidence 0.14 Published 1995 Journal Psychopharmacology (Berl.) Section Abstract Doc Link 8539320 Disease Relevance 0 Pain Relevance 0.39
Since a role of enkephalin in the regulation of bone remodeling has been suggested previously and since Leu-enkephalin is known to be cleaved by Phex, we analyzed whether Penk expression in osteoblasts is physiologically relevant.
Protein_catabolism (cleaved) of Leu-enkephalin in osteoblasts associated with enkephalin
14) Confidence 0.05 Published 2010 Journal Calcif. Tissue Int. Section Abstract Doc Link 20204609 Disease Relevance 0.15 Pain Relevance 0.20
Therefore, the prolongation of the antinociception induced by both dynorphins in the presence of phosphoramidon, may be due to inhibition of [Leu5]enkephalin-Arg6 degradation.
Protein_catabolism (degradation) of enkephalin-Arg6 associated with antinociception and enkephalin
15) Confidence 0.04 Published 1996 Journal Eur. J. Pharmacol. Section Abstract Doc Link 8957219 Disease Relevance 0 Pain Relevance 1.57
The obtained values for KA and e(rel) suggest that: (i) incorporation of Cys(O2NH2)2 in the molecule of [Leu5]enkephalin highly increases the efficacy and does not change significantly the affinity of the respective analogues to delta-opioid receptors; [Cys(O2NH2)2, Leu5]enkephalin has higher affinity than DPDPE, but is less resistant to enzyme degradation; the effect of this modification on the efficacy is decreased when methionine is in position 5; (ii) D-configuration of Cys(O2NH2)2-containing analogues increases their peptidase resistance, but reduces efficacy and affinity of the peptides towards delta-opioid receptors; (iii) the substitution of Cys(O2NH2) with Hcy(O2NH2) reduces the efficacy, affinity and potency of the respective analogues and maintains their sensitivity to endogenous peptidases; (iv) the substitution of the sulfonamide group with benzyl group in the molecule of Cys in position 2 decreases their efficacy and affinity toward delta-opioid receptors, but attaches resistance to enzyme degradation.
Protein_catabolism (degradation) of enkephalin associated with delta opioid receptors, enkephalin and potency
16) Confidence 0.03 Published 2004 Journal Eur. J. Pharmacol. Section Abstract Doc Link 15364002 Disease Relevance 0 Pain Relevance 0.92
In the enzymatic degradation using high-performance liquid chromatography, both tripeptides showed good enzymatic stability after 25 hr of incubation with solubilized enzymes of mouse brain or spinal cord, in contrast to a rapid degradation of Met-enkephalin.
Protein_catabolism (degradation) of Met-enkephalin in spinal cord associated with enkephalin and spinal cord
17) Confidence 0.02 Published 1992 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 1331414 Disease Relevance 0 Pain Relevance 0.71

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox